These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17346111)

  • 21. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment.
    Hashimoto Y; Tazawa H; Teraishi F; Kojima T; Watanabe Y; Uno F; Yano S; Urata Y; Kagawa S; Fujiwara T
    PLoS One; 2012; 7(6):e39292. PubMed ID: 22720091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
    Fang L; Cheng Q; Li W; Liu J; Li L; Xu K; Zheng J
    Virus Res; 2014 Mar; 181():61-71. PubMed ID: 24463503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner.
    Kim E; Kim JH; Shin HY; Lee H; Yang JM; Kim J; Sohn JH; Kim H; Yun CO
    Hum Gene Ther; 2003 Oct; 14(15):1415-28. PubMed ID: 14577922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice.
    Lin WH; Yeh SH; Yang WJ; Yeh KH; Fujiwara T; Nii A; Chang SS; Chen PJ
    Int J Cancer; 2013 Mar; 132(6):1451-62. PubMed ID: 22886913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
    Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
    Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic viruses driven by tumor-specific promoters.
    Hardcastle J; Kurozumi K; Chiocca EA; Kaur B
    Curr Cancer Drug Targets; 2007 Mar; 7(2):181-9. PubMed ID: 17346110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.
    Kyo S; Takakura M; Fujiwara T; Inoue M
    Cancer Sci; 2008 Aug; 99(8):1528-38. PubMed ID: 18754863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
    Sakakibara A; Tsukuda M; Kondo N; Ishiguro Y; Kimura M; Fujita K; Takahashi H; Matsuda H
    Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
    Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
    Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo imaging of human cancer with telomerase-specific replication-selective adenovirus.
    Fujiwara T
    Methods Mol Biol; 2012; 872():129-39. PubMed ID: 22700408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter.
    Davis JJ; Wang L; Dong F; Zhang L; Guo W; Teraishi F; Xu K; Ji L; Fang B
    Cancer Gene Ther; 2006 Jul; 13(7):720-3. PubMed ID: 16485010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.
    Li G; Kawashima H; Ogose A; Ariizumi T; Xu Y; Hotta T; Urata Y; Fujiwara T; Endo N
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):1037-51. PubMed ID: 21193997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
    Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma.
    Su CQ; Wang XH; Chen J; Liu YJ; Wang WG; Li LF; Wu MC; Qian QJ
    World J Gastroenterol; 2006 Dec; 12(47):7613-20. PubMed ID: 17171789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin).
    Ouchi M; Kawamura H; Urata Y; Fujiwara T
    Invest New Drugs; 2009 Jun; 27(3):241-5. PubMed ID: 18754077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.